RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Clinuvel Pharmaceuticals Stock

Clinuvel Pharmaceuticals P/S 2025

Clinuvel Pharmaceuticals P/S

6.31

Ticker

CUV.AX

ISIN

AU000000CUV3

WKN

A0JEGY

As of Jul 26, 2025, Clinuvel Pharmaceuticals's P/S ratio stood at 6.31, a -2.32% change from the 6.46 P/S ratio recorded in the previous year.

The Clinuvel Pharmaceuticals P/S history

Clinuvel Pharmaceuticals Aktienanalyse

What does Clinuvel Pharmaceuticals do?

Clinuvel Pharmaceuticals Ltd is a biopharmaceutical company that specializes in researching, developing, and marketing drugs targeting skin pigmentation. The company was founded in 1987 and is headquartered in Melbourne, Australia. It has become a leading expert in the field of light and pigment medicine since its establishment. Clinuvel's business model focuses on utilizing innovative technologies and scientific research to develop new products and therapies that benefit patients worldwide. The company specializes in developing safe and effective drugs based on research in therapeutic areas such as skin pigment disorders and skin cancer prevention. In recent years, the company has expanded its various divisions to meet market demand and extend innovations to other areas of medicine. Clinuvel's main divisions are Pharmaceuticals and Nutraceuticals. Clinuvel's pharmaceutical division specializes in developing new drugs and therapies for modulating skin pigmentation. The company is particularly known for its flagship product, SCENESSE, an implant that allows people with the rare condition erythropoietic protoporphyria (EPP) to live without pain in the sun. SCENESSE has received European and Australian approvals and is prescribed worldwide by a growing network of treatment centers. Clinuvel's nutraceutical division focuses on developing dietary supplements and advising patients who want to improve their skin from within. This includes products like Cuvita, a dietary supplement containing antioxidants and other nutrients that can contribute to the health of hair, skin, and nails. Clinuvel has expanded its business models to meet the needs of patients in different regions of the world. For example, the company has developed a comprehensive integration strategy in Europe to promote research, development, and marketing of innovative products and therapies. Overall, Clinuvel Pharmaceuticals is a company that focuses on developing innovative drugs and therapies in the field of light and pigment medicine. It is known for its advanced research, successful development of SCENESSE, and commitment to patients worldwide. It will be interesting to see how the divisions develop in the future, but innovative drugs and therapies are definitely an important part of Clinuvel's future. Clinuvel Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Clinuvel Pharmaceuticals's P/S Ratio

Clinuvel Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Clinuvel Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Clinuvel Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Clinuvel Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Clinuvel Pharmaceuticals stock

What is the price-to-earnings ratio of Clinuvel Pharmaceuticals?

The price-earnings ratio of Clinuvel Pharmaceuticals is currently 6.31.

How has the price-earnings ratio of Clinuvel Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Clinuvel Pharmaceuticals has increased by -2.32% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Clinuvel Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Clinuvel Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Clinuvel Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Clinuvel Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Clinuvel Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Clinuvel Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Clinuvel Pharmaceuticals?

Some factors that influence the price-earnings ratio of Clinuvel Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Clinuvel Pharmaceuticals pay?

Over the past 12 months, Clinuvel Pharmaceuticals paid a dividend of 0.07 AUD . This corresponds to a dividend yield of about 0.6 %. For the coming 12 months, Clinuvel Pharmaceuticals is expected to pay a dividend of 0.08 AUD.

What is the dividend yield of Clinuvel Pharmaceuticals?

The current dividend yield of Clinuvel Pharmaceuticals is 0.6 %.

When does Clinuvel Pharmaceuticals pay dividends?

Clinuvel Pharmaceuticals pays a quarterly dividend. This is distributed in the months of October, October, October, October.

How secure is the dividend of Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals paid dividends every year for the past 14 years.

What is the dividend of Clinuvel Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.08 AUD are expected. This corresponds to a dividend yield of 0.69 %.

In which sector is Clinuvel Pharmaceuticals located?

Clinuvel Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Clinuvel Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Clinuvel Pharmaceuticals from 9/20/2024 amounting to 0.071 AUD, you needed to have the stock in your portfolio before the ex-date on 9/5/2024.

When did Clinuvel Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/20/2024.

What was the dividend of Clinuvel Pharmaceuticals in the year 2024?

In the year 2024, Clinuvel Pharmaceuticals distributed 0.071 AUD as dividends.

In which currency does Clinuvel Pharmaceuticals pay out the dividend?

The dividends of Clinuvel Pharmaceuticals are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Clinuvel Pharmaceuticals

Our stock analysis for Clinuvel Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Clinuvel Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.